News
FBRX
33.90
+29.04%
7.63
Forte Biosciences Shares Hit 52-Week High After $150M Public Offering Prices
Dow Jones · 11h ago
BUZZ-U.S. STOCKS ON THE MOVE-Zscaler, Carlyle, Weight Watchers
Reuters · 11h ago
Forte Biosciences Up Nearly 33%, on Pace for Largest Percent Increase Since May 2025 -- Data Talk
Dow Jones · 12h ago
BlackBerry Posts Upbeat Q4 Results, Joins Constellation Brands, Marvell Technology And Other Big Stocks Moving Higher On Thursday
Benzinga · 12h ago
BUZZ-Forte Biosciences soars after $150 mln equity raise
Reuters · 13h ago
BUZZ-U.S. STOCKS ON THE MOVE-Marvell Technology, Tempus AI, Energy Vault
Reuters · 14h ago
BUZZ-Forte Biosciences gains premarket after $150 mln equity raise
Reuters · 15h ago
Forte Biosciences Prices $150 Million Public Offering
TipRanks · 17h ago
Forte Biosciences prices 5.71M shares at $26.27 in $150M capital raise
Seeking Alpha · 18h ago
*Forte Biosciences Announces Pricing of $150M Public Offering
Dow Jones · 1d ago
*Forte Biosciences: Granted Underwriters 30-Day Option to Purchase Up to Additional 856,490 Shares at Public Offering Price > FBRX
Dow Jones · 1d ago
*Forte Biosciences: Intends to Use Proceeds for Working Capital, Other General Corporate Purposes >FBRX
Dow Jones · 1d ago
*Forte Biosciences: Public Offering of 5.7M Shares Priced at $26.27 Each >FBRX
Dow Jones · 1d ago
Forte Biosciences 5.71M share Spot Secondary priced at $26.27
TipRanks · 1d ago
Forte Biosciences prices USD 150 million follow-on equity offering at USD 26.27/share
Reuters · 1d ago
FORTE BIOSCIENCES INC - ANNOUNCES PRICING OF 5,709,936 SHARE PUBLIC OFFERING AT $26.27 PER SHARE
Reuters · 1d ago
BUZZ-Forte Biosciences falls after launching stock offering
Reuters · 1d ago
Forte Biosciences announces common stock offering, no amount given
TipRanks · 1d ago
Forte Biosciences launches public stock offering to fund operations
Seeking Alpha · 1d ago
Forte Biosciences Reveals Proposed Public Offering; No Size Disclosed
Benzinga · 1d ago
More
Webull provides a variety of real-time FBRX stock news. You can receive the latest news about Forte Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About FBRX
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.